Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 4, 2010 - Issue 2
Submit an article Journal homepage
726
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Multidrug-resistant tuberculosis: standardized or individualized treatment? The question has already been answered

Rafael Laniado-Laborín Emiliano Zapata 1423, Zona Centro, Tijuana, Baja California, CP 22000, Mexico. [email protected]
Pages 143-146 | Published online: 09 Jan 2014

References

  • Han LL, Sloutsky A, Canales R et al. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens. Int. J. Tuberc. Lung Dis.9, 818–821 (2005).
  • Nathanson E, Lambregts-van Weezenbeek C, Rich ML et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg. Infect. Dis.12, 1389–1397 (2006).
  • World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009. WHO/HTM/TB/2009.411. WHO, Geneva, Switzerland (2009).
  • Pablos-Mendez A, Raviglione MC, Laszlo A et al. for the World Health Organization – International Union Against Tuberculosis and Lung Disease Working Group on Drug Resistance Surveillance. Global surveillance for antituberculosis-drug resistance, 1994–1997. N. Engl. J. Med.339, 139 (1998).
  • Chana ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr. Opin. Infect. Dis.21, 587–595 (2008).
  • Lan NTN, Lademarco MF, Binkin NJ, Tung LB, Quy HT, Cĵ NV. A case series: initial outcome of persons with multidrug- resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam. Int. J. Tuberc. Lung Dis.5, 575–578 (2001).
  • World Health Organization. Treatment of tuberculosis: guidelines for national programmes (3rd edition). WHO/CDS/TB/2003.313. WHO, Geneva, Switzerland (2003).
  • Mak A, Thomas A, del Granado M, Zaleskis R, Mouzafarova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am. J. Respir. Crit. Care Med.178, 306–312 (2009).
  • Espinal MA, Kim SJ, Suarez PG et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcome in 6 countries. JAMA283, 2537–2545 (2000).
  • Leimane V, Riekstina V, Holtz TH et al. Clinical outcome of individualised treatment of multidrugresistant tuberculosis in Latvia: a retrospective cohort study. Lancet365, 318–326 (2005).
  • Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M, Raviglione MC. Frequency of recurrence among MDR-TB cases ‘successfully’ treated with standardised short-course chemotherapy. Int. J. Tuberc. Lung Dis.6, 858–864 (2002).
  • Caminero JA. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int. J. Tuberc. Lung Dis.12, 869–877 (2008).
  • Espinal MA. Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. Int. J. Tuberc. Lung Dis.7, 607–608 (2003).
  • Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur. Respir. J.25, 928–936 (2005).
  • World Health Organization. Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis. WHO/CDS/TB/2000.279. WHO, Geneva, Switzerland (2000).
  • World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update. WHO/HTM/TB/2008.402. WHO, Geneva, Switzerland (2008).
  • Drug-Resistant Tuberculosis: A Survival Guide for Clinicians (Second Edition). Francis J Curry National Tuberculosis Center and California Department of Public Health, CA, USA, 33–56 (2008).
  • Suárez PG, Floyd K, Portocarrero J et al. Feasibility and cost–effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet359, 1980–1989 (2002).
  • Mitnick C, Bayona J, Palacios E et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N. Engl. J. Med.348, 119–128 (2003).
  • Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int. J. Tuberc. Lung Dis.8, 361–368 (2004).
  • Yong Kim J, Shakow A, Mate K, Vanderwarker C, Gupta R, Farmer P. Limited good and limited vision: multidrug-resistant tuberculosis and global health policy. Social Sci. Med.61, 847–859 (2005).
  • Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med.4(11), e292 (2005).
  • Iseman M. Tailoring a time-bomb. Am. Rev. Respir. Dis.132, 735 (1985).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.